Objective: To investigate the effectiveness and safety of CT-guided percutaneous radiofrequency ablation for the treatment of secondary hyperparathyroidism (SHPT) in chronic renal failure. Methods: Thirty patients with SHPT in our hospital were selected as the study subjects.
Preoperative CT examinations confirmed that there were 1 to 4 hyperplastic parathyroid tissues. Under the guidance of CT, radiofrequency ablation of the hyperplastic parathyroid tissues was performed to detect ablation The levels of PTH, blood Ca, and blood P before and after 10 min, 1 d,
1 week, 1 month, 6 months, and 1 year of ablation were observed to observe the improvement of clinical symptoms and the occurrence of complications. Results: First, the patients' blood PTH levels at 10 min, 1 d, 1 week, 1 month, 6 months, and 1 year after ablation were significantly
lower than those before the ablation (P < 0.05); 10 min, 1 d, Blood Ca levels at 1 week, 1 month, 6 months, and 1 year were significantly lower than those before ablation (P < 0.05); 10 min, 1 d, 1 week, 1 month, 6 months, and 1 month after ablation The blood P level
in 2015 was significantly lower than that before ablation (P < 0.05). Second, the symptoms of bone pain, itching of the skin, muscle weakness, and anorexia were significantly improved after ablation, and hoarseness occurred in 3 cases. The rate was 10%, all of which remitted spontaneously
within 1 week after operation; 2 cases of severe hypocalcemia occurred with a rate of 6.6%. All patients had remission after timely calcium supplementation, and all patients did not relapse. Conclusion: CT-guided percutaneous radiofrequency ablation is a safe and effective method for
the treatment of SHPT, which can significantly improve the symptoms of renal bone disease and improve the quality of life.
Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer
